Systemic sclerosis and the heart: Current diagnosis and management

Current Opinion in Rheumatology

Volumn 23, Issue 6, 2011, Pages 545-554

  Desai, Chintan S ^a   Lee, Daniel C ^a   Shah, Sanjiv J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Echocardiography; Myocardial fibrosis; Myocardial perfusion; Natriuretic peptides; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NATRIURETIC FACTOR; RANOLAZINE; STEROID; VERAPAMIL;

ANGINA PECTORIS; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIAGNOSTIC PROCEDURE; EPIDEMIC; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HIGH RISK PATIENT; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC SCLEROSIS; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; TISSUE DOPPLER IMAGING;

BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 82955225155     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834b8975     Document Type: Review

References (81)

1. Meune C, Vignaux O, Kahan A, et al. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010; 103:46-52.
2. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl 3):iii45-iii48.
3. Champion HC. The heart in scleroderma. Rheum Dis Clin North Am 2008; 34:181-190. (Pubitemid 351329461)
4. Shah SJ, Kahan A. Cardiac involvement: evaluation and management. In: Varga J, Denton C, Wigley F, editors. Scleroderma: from pathogenesis to comprehensive management. New York: Springer; 2011.
5. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69:218-221.
6. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81:139-153. (Pubitemid 34218569)
7. Domsic RT, Rodriguez-Reyna T, Lucas M, et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70:104-109.
8. Manno RL, Wigley FM, Gelber AC, Hummers LK. Late-age onset systemic sclerosis. J Rheumatol 2011; 38:1317-1325.
9. El-Shafie MM, Salem SS, Moghazi AA. Left ventricular myocardial ischemia in collagen disease associated with pulmonary hypertension: an evaluation by rest-stress gated SPECT and coronary angiography. Nucl Med Commun 2011; 32:641-648.
10. Vogel-Claussen J, Skrok J, Shehata ML, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 2011; 258:119-127.
11. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269-277.
12. Czirjak L, Kumanovics G, Varju C, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67:59-63.
13. Joven BE, Almodovar R, Carmona L, et al. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39:285-293.
14. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815.
15. Plazak W, Kopec G, Tomkiewicz-Pajak L, et al. Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study. Acta Cardiol 2011; 66:159-165.
16. Rosato E, Maione S, Vitarelli A, et al. Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables. Rheumatol Int 2009; 29:913-919.
17. Plaksej R, Kosmala W, Frantz S, et al. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 2009; 27:2483-2491.
18. Can I, Onat AM, Aytemir K, et al. Detecting subclinical biventricular impairment in scleroderma patients by use of pulsed-wave tissue Doppler imaging. Tex Heart Inst J 2009; 36:31-37.
19. Allanore Y, Wahbi K, Borderie D, et al. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2009; 68:1885-1889.
20. Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58:1803-1809. (Pubitemid 351847535)
21. Kepez A, Akdogan A, Sade LE, et al. Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. Echocardiography 2008; 25:191-197. (Pubitemid 351199002)
22. Allanore Y, Meune C, Kahan A. Outcome measures for heart involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47 (Suppl 5):v51-v53.
23. Abraham TP, Dimaano VL, Liang HY. Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation 2007; 116:2597-2609. (Pubitemid 350179223)
24. Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 2010; 37:993-999.
25. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107-133.
26. Horton KD, Meece RW, Hill JC. Assessment of the right ventricle by echocardiography: a primer for cardiac sonographers. J Am Soc Echocardiogr 2009; 22:776-792.
27. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685-713.
28. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003; 41:1021-1027. (Pubitemid 36315548)
29. Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:268-276.
30. Hesselstrand R, Wildt M, Ekmehag B, et al. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011; 40:127-132.
31. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35:95-104.
32. Allanore Y, Meune C. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009; 27:59-63.
33. Ciurzynski M, Bienias P, Lichodziejewska B, et al. Noninvasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 2008; 27:991-997.
34. Choi HJ, Shin YK, Lee HJ, et al. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 2008; 27:437-442. (Pubitemid 351404297)
35. Giannoni A, Tani C, Clerico A, et al. When the heart is burning: aminoterminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. Int J Cardiol 2011; 148:161-167.
36. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824-839.
37. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92:843-849. (Pubitemid 43799232)
38. Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003; 48:3503-3508. (Pubitemid 37531916)
39. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal probrain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97:1230-1236. (Pubitemid 37337021)
40. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27:1485-1494. (Pubitemid 43998084)
41. Mathai SC, Hassoun PM. N-terminal brain natriuretic peptide in sclerodermaassociated pulmonary arterial hypertension. Eur Heart J 2007; 28:140-141; author reply 141. (Pubitemid 46134968)
42. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58:284-291.
43. Carlo-Stella N, Belloli L, Biondi ML, et al. Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? Clin Rheumatol 2009; 28:241-242.
44. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37:2064-2070.
45. Mok MY, Lau CS, Chiu SS, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum 2011; 63:1387-1395.
46. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68:1878-1884.
47. Bezante GP, Rollando D, Sessarego M, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007; 34:2431-2437. (Pubitemid 350230667)
48. Geyer H, Caracciolo G, Abe H, et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 2010; 23:351-369; quiz 453-455.
49. Blessberger H, Binder T. Non-invasive imaging: two dimensional speckle tracking echocardiography: basic principles. Heart 2010; 96:716-722.
50. Pavlopoulos H, Nihoyannopoulos P. Strain and strain rate deformation parameters: from tissue Doppler to 2D speckle tracking. Int J Cardiovasc Imaging 2008; 24:479-491.
51. Teske AJ, De Boeck BW, Melman PG, et al. Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking. Cardiovasc Ultrasound 2007; 5:27.
52. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52:1574-1580.
53. Messroghli DR, Greiser A, Frohlich M, et al. Optimization and validation of a fullyintegrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26:1081-1086. (Pubitemid 47548170)
54. Schelbert EB, Testa SM, Meier CG, et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson 2011; 13:16.
55. Lee DC, Johnson NP. Quantification of absolute myocardial blood flow by magnetic resonance perfusion imaging. JACC Cardiovasc Imaging 2009; 2:761-770.
56. Marwick TH. Measurement of strain and strain rate by echocardiography: ready for prime time? J Am Coll Cardiol 2006; 47:1313-1327.
57. Popovic ZB, Kwon DH, Mishra M, et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr 2008; 21: 1299-1305.
58. Matias C, Isla LP, Vasconcelos M, et al. Speckle-tracking-derived strain and strain-rate analysis: a technique for the evaluation of early alterations in right ventricle systolic function in patients with systemic sclerosis and normal pulmonary artery pressure. J Cardiovasc Med (Hagerstown) 2009; 10:129-134.
59. Schattke S, Knebel F, Grohmann A, et al. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler tissue and speckle tracking echocardiography study. Cardiovasc Ultrasound 2010; 8:3.
60. Vohringer M, Mahrholdt H, Yilmaz A, et al. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz 2007; 32:129-137. (Pubitemid 46980389)
61. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010; 122:138-144.
62. Mizuno R, Fujimoto S, Saito Y, et al. Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study. Eur J Heart Fail 2010; 12:268-275.
63. George BJ, Kwan MD, Morris MJ. Isolated right ventricular failure in scleroderma heart disease. Cardiol Rev 2004; 12:279-281. (Pubitemid 39121682)
64. Giunta A, Tirri E, Maione S, et al. Right ventricular diastolic abnormalities in systemic sclerosis: relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000; 59:94-98. (Pubitemid 30305604)
65. Gonzalez A, Seres L, Ferrer E, et al. Isolated right ventricular systolic dysfunction in scleroderma. Rev Esp Cardiol 2008; 61:990-991.
66. Hsiao SH, Lee CY, Chang SM, et al. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 2006; 19:507-514.
67. Huez S, Roufosse F, Vachiery JL, et al. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? Eur Respir J 2007; 30:928-936. (Pubitemid 351194797)
68. Lee CY, Chang SM, Hsiao SH, et al. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion. Echocardiography 2007; 24:118-125.
69. Lindqvist P, Caidahl K, Neuman-Andersen G, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest 2005; 128:755-763. (Pubitemid 41140506)
70. Meune C, Allanore Y, Devaux JY, et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol 2004; 31:1941-1945. (Pubitemid 39336717)
71. Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56:393-394. (Pubitemid 27305431)
72. Dunne JV, Chou JP, Viswanathan M, et al. Cardiac tamponade and large pericardial effusions in systemic sclerosis: a report of four cases and a review of the literature. Clin Rheumatol 2011; 30:433-438.
73. Dal-Bianco JP, Sengupta PP, Mookadam F, et al. Role of echocardiography in the diagnosis of constrictive pericarditis. J Am Soc Echocardiogr 2009; 22:24-33.
74. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46:428-440.
75. Ridolfi RL, Bulkley BH, Hutchins GM. The cardiac conduction system in progressive systemic sclerosis: clinical and pathologic features of 35 patients. Am J Med 1976; 61:361-366.
76. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis 2008; 51:58-73. (Pubitemid 351958494)
77. Assassi S, Del Junco D, Sutter K, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009; 61:1403-1411.
78. Bienias P, Ciurzynski M, Glinska-Wielochowska M, et al. Heart rate turbulence assessment in systemic sclerosis: the role for the detection of cardiac autonomic nervous system dysfunction. Rheumatology (Oxford) 2010; 49:355-360.
79. Wozniak J, Dabrowski R, Luczak D, et al. Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma. J Rheumatol 2009; 36:191-196.
80. Bielous-Wilk A, Poreba M, Staniszewska-Marszalek E, et al. Electrocardiographic evaluation in patients with systemic scleroderma and without clinically evident heart disease. Ann Noninvasive Electrocardiol 2009; 14:251-257.
81. Bernardo P, Conforti ML, Bellando-Randone S, et al. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. J Rheumatol 2011; 38:1617-1621.